Fig. 2From: Pathologic response as an early endpoint for survival following neoadjuvant androgen deprivation therapy plus abiraterone acetate for metastatic prostate cancerKaplan–Meier analysis for progression-free survival in patients between pCR and non-pCRBack to article page